Literature DB >> 27964792

Cardiovascular disease in inflammatory rheumatic diseases.

Santos Castañeda1, Michael T Nurmohamed2, Miguel A González-Gay3.   

Abstract

Chronic inflammatory rheumatic diseases (IRD), including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, are prevalent conditions worldwide, with a considerable burden on healthcare systems. They are associated with increased cardiovascular (CV) morbidity and mortality. In this review, we focused on the epidemiology, traditional CV risk factors, genetics, and the link between chronic inflammation, atherosclerosis, and CV disease. Remarkably, patients with IRD have higher vulnerability to atheromatous plaques. The risk of unstable plaques is higher in patients with rheumatoid arthritis than in controls. Active disease is a characteristic ascribed to vulnerability and rupture of plaques and a cause of thrombosis in IRD. Management of CV risk in patients with IRD includes optimal control of disease activity. CV risk stratification by applying risk charts is also essential. Imaging techniques might be useful to determine the actual CV risk of patients with IRD who are included in the category of intermediate or moderate CV risk.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ankylosing spondylitis; Cardiovascular disease; Cardiovascular risk assessment; Cardiovascular risk factors; Psoriatic arthritis; Rheumatoid arthritis; Spondyloarthritis

Mesh:

Year:  2016        PMID: 27964792     DOI: 10.1016/j.berh.2016.10.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  43 in total

1.  Inflammation: NSAIDs and cardiovascular risk in arthritis.

Authors:  Miguel A González-Gay; Carlos González-Juanatey
Journal:  Nat Rev Cardiol       Date:  2017-01-05       Impact factor: 32.419

2.  Disease severity impacts the relationship of apelin with arterial function in patients with rheumatoid arthritis.

Authors:  Sulé Gunter; Chanel Robinson; Gavin R Norton; Angela J Woodiwiss; Linda Tsang; Aletta M E Millen; Patrick H Dessein
Journal:  Clin Rheumatol       Date:  2018-02-08       Impact factor: 2.980

3.  Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis.

Authors:  Edit Végh; György Kerekes; Anita Pusztai; Attila Hamar; Szilvia Szamosi; Andrea Váncsa; Levente Bodoki; Lilla Pogácsás; Fruzsina Balázs; Katalin Hodosi; Andrea Domján; Sándor Szántó; Zoltán Nagy; Zoltán Szekanecz; Gabriella Szűcs
Journal:  Rheumatol Int       Date:  2019-12-17       Impact factor: 2.631

Review 4.  Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches.

Authors:  Ann M Chodara; Aimée Wattiaux; Christie M Bartels
Journal:  Curr Rheumatol Rep       Date:  2017-04       Impact factor: 4.592

Review 5.  Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.

Authors:  Santos Castañeda; Carlos González-Juanatey; Miguel A González-Gay
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

6.  Brain Stimulation Differentially Modulates Nociception and Inflammation in Aversive and Non-aversive Behavioral Conditions.

Authors:  G S Bassi; A Kanashiro; G J Rodrigues; F Q Cunha; N C Coimbra; L Ulloa
Journal:  Neuroscience       Date:  2018-05-18       Impact factor: 3.590

7.  Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease.

Authors:  Alessandro Giollo; Andrea Dalbeni; Giovanni Cioffi; Federica Ognibeni; Davide Gatti; Luca Idolazzi; Giovanni Orsolini; Pietro Minuz; Maurizio Rossini; Cristiano Fava; Ombretta Viapiana
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

8.  Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.

Authors:  M Frodlund; A Vikerfors; G Grosso; T Skogh; J Wetterö; K Elvin; I Gunnarsson; A Kastbom; Ö Dahlström; J Rönnelid; E Svenungsson; C Sjöwall
Journal:  Clin Exp Immunol       Date:  2018-09-12       Impact factor: 4.330

9.  Transcription Factor MAFF (MAF Basic Leucine Zipper Transcription Factor F) Regulates an Atherosclerosis Relevant Network Connecting Inflammation and Cholesterol Metabolism.

Authors:  Moritz von Scheidt; Yuqi Zhao; Thomas Q de Aguiar Vallim; Nam Che; Michael Wierer; Marcus M Seldin; Oscar Franzén; Zeyneb Kurt; Shichao Pang; Dario Bongiovanni; Masayuki Yamamoto; Peter A Edwards; Arno Ruusalepp; Jason C Kovacic; Matthias Mann; Johan L M Björkegren; Aldons J Lusis; Xia Yang; Heribert Schunkert
Journal:  Circulation       Date:  2021-02-25       Impact factor: 29.690

10.  Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study.

Authors:  Dorien M C F Sluijsmans; Daphne C Rohrich; Calin D Popa; Bart J F van den Bemt
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.